Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Juan Miguel Gil Gil"'
Autor:
Salvador Blanch, Juan Miguel Gil-Gil, Miriam Arumí, Elena Aguirre, Miguel Ángel Seguí, Manuel Atienza, Silvia Díaz-Cerezo, Alberto Molero, José Manuel Cervera, Joaquín Gavilá
Publikováno v:
Clinical and Translational Oncology.
Introduction/objectives To describe abemaciclib use in patients with hormone receptor-positive, human epidermal growth factor receptor-negative (HR+/HER2−) metastatic breast cancer (mBC) who participated in the Named Patient Use program (NPU) in Sp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f37bc279332f0f7607ff636650b20d49
https://doi.org/10.1007/s12094-023-03159-9
https://doi.org/10.1007/s12094-023-03159-9
Autor:
Michelle Joy Naughton, David Zahrieh, Michael Gnant, Nicholas Zdenkowski, Julie Lemieux, Jun J Mao, Vesna Bjelic-Radisic, Eileen Shinn, Marija Balic, Christoph Thomssen, Jane Neisel, Manuel Ruiz-Echarri, Sibylle Loibl, Claudine Isaacs, David Cameron, Fernando Manuel Henao Carrasco, Matthew Goetz, Viktor Wette, Gustavo Werutsky, Hope Rugo, Marcus Vetter, Ling-Ming Tseng, Kathy Miller, Florian Fitzal, Juan Miguel Gil Gil, Haeseong Park, Barbro Linderholm, Emilio Bajetta, Zoneddy Dayao, Aleix Prat, Karin Ehrhardt, Otto Metzger, Amal Arahmani, Ernest Law, Ann Partridge, Lisa Carey, Alex Zoroufy, Amylou Dueck, Dominik Hlauschek, Angela DeMichele, Erica Mayer
Publikováno v:
Cancer Research. 82:P4-10
Background: Quality of life (QOL) in breast cancer patients (pts) can be greatly impacted by initial treatment and ongoing therapy, particularly if side effects and symptoms are not well tolerated. The PALLAS trial investigated whether the addition o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f2437005b23fbc8bc68537113e1f263
https://doi.org/10.1158/1538-7445.sabcs21-p4-10-01
https://doi.org/10.1158/1538-7445.sabcs21-p4-10-01
Autor:
Almudena del Castillo, Carlos Rubio-Terrés, Felisa Canorea, Juan Miguel Gil Gil, Paloma González
Publikováno v:
Clinical and Translational Oncology. 8:339-348
To compare the efficiency of adjuvant therapy with aromatase inhibitors or with tamoxifen in postmenopausal women with operable breast cancer and positive estrogen receptors.A cost-utility analysis was performed based on a Markov model, from the Span
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cada209f71c6bd75323d424f96b8cf90
https://doi.org/10.1007/s12094-006-0180-z
https://doi.org/10.1007/s12094-006-0180-z
Autor:
Publio González, Juan Miguel Gil Gil, Carlos Rubio-Terrés, A Lluch, F Canorea, A Del Castillo
Publikováno v:
Value in Health. (6):A37-A38
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72faa456c2c865647bd706ccecee7036